Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design.
Business Wire › November 17, 2009
Linked as:
Extract
Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design.
CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets. The Committee disagreed with the safety mar...
See the full content of this document
Sponsored links
